[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [Alnylam Pharmaceuticals, Inc.](/topic/alnylam-pharmaceuticals-inc) ### Sentiment: XX%  [Sentiment 24-Hour Time-Series Raw Data](/topic/alnylam-pharmaceuticals-inc/time-series/sentiment.tsv) **Current Value**: XX% **Daily Average**: XX% **1 Week**: XXX% +17% **1 Month**: XX% +35% **6 Months**: XX% +30% **1 Year**: XX% +13% **1-Year High**: XXX% on 2025-07-29 **1-Year Low**: XX% on 2025-05-28 **Most Supportive Themes** - **Positive Data from HELIOS-B Study:** (35%) New data from the HELIOS-B Phase X study demonstrates lower rates of gastrointestinal events in ATTR-CM patients treated with Vutrisiran, supporting its role as a first-line therapy. - **Amvuttra Sales and Revenue Guidance:** (20%) Alnylam reported strong Amvuttra sales and raised its 2025 revenue guidance, indicating positive financial performance. - **First Patient Dosed in ZENITH Trial:** (15%) Alnylam announced the first patient dosed in the ZENITH Global Phase X cardiovascular outcomes trial of Zilebesiran, signaling progress in its clinical pipeline. **Most Critical Themes** - **FDA Crackdown and Ad Pull:** (10%) Alnylam pulled TV ads following a crackdown on drug industry advertising, which may raise concerns. - **Negative Sentiment on X:** (20%) A large percentage of X posts express negative sentiment, with many users expressing concerns about the company. Network engagement breakdown: | Network | Positive | % | Neutral | % | Negative | % | | ------- | -------- | - | ------- | - | -------- | - | | X | XXXXX | XX% | XXXXX | XX% | XXX | X% | | News | X | X% | X | X% | X | X% | | | | | | | | | | Total | XXXXX | XX% | XXXXX | XX% | XXX | X% |
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Sentiment: XX%
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
1 Week: XXX% +17%
1 Month: XX% +35%
6 Months: XX% +30%
1 Year: XX% +13%
1-Year High: XXX% on 2025-07-29
1-Year Low: XX% on 2025-05-28
Most Supportive Themes
- Positive Data from HELIOS-B Study: (35%) New data from the HELIOS-B Phase X study demonstrates lower rates of gastrointestinal events in ATTR-CM patients treated with Vutrisiran, supporting its role as a first-line therapy.
- Amvuttra Sales and Revenue Guidance: (20%) Alnylam reported strong Amvuttra sales and raised its 2025 revenue guidance, indicating positive financial performance.
- First Patient Dosed in ZENITH Trial: (15%) Alnylam announced the first patient dosed in the ZENITH Global Phase X cardiovascular outcomes trial of Zilebesiran, signaling progress in its clinical pipeline.
Most Critical Themes
- FDA Crackdown and Ad Pull: (10%) Alnylam pulled TV ads following a crackdown on drug industry advertising, which may raise concerns.
- Negative Sentiment on X: (20%) A large percentage of X posts express negative sentiment, with many users expressing concerns about the company.
Network engagement breakdown:
| Network | Positive | % | Neutral | % | Negative | % |
|---|---|---|---|---|---|---|
| X | XXXXX | XX% | XXXXX | XX% | XXX | X% |
| News | X | X% | X | X% | X | X% |
| Total | XXXXX | XX% | XXXXX | XX% | XXX | X% |